Advertisement

Topics

Latest "Line Management" News Stories

11:52 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "Line Management" found in our extensive news archives from over 250 global news sources.

More Information about Line Management on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Line Management for you to read. Along with our medical data and news we also list Line Management Clinical Trials, which are updated daily. BioPortfolio also has a large database of Line Management Companies for you to search.

Showing "Line Management" News Articles 1–25 of 10,000+

Relevant

Wound Care Management

Primary care physicians usually can care for minor wounds in their offices. This article highlights key elements in first-line management.


The painfully fine line of pain management

I’ve been practicing as an interventional pain management physician for over six years. It was a long road to get here — four years of medical school, four years of residency in anesthesiology and one year of fellowship (in addition to the four years of undergraduate education). So people say, “You must really love what […]

Kochava Named LINE Ads Measurement Partner

LINE joins the industry's largest network and publisher integrations with Kochava. Marketers can now apply the same granular tracking on the expansive inventory that LINE Read more...


Klox Technologies announces positive top-line results from a pivotal study of Phovia™ for the management of Canine Deep Pyoderma

DUBLIN, Ireland, July 02, 2018 (GLOBE NEWSWIRE) -- Klox Technologies Limited, a subsidiary of Klox Technologies Inc. (‘KTI’) has announced they have completed a pivotal study of Phovia for the management of Canine Deep Pyoderma. The 80-patient study met all endpoints and demonstrated that Phovia significantly reduces time to clinical resolution while reducing the duration of antibiotic use...

First- and Second-line Therapy for Moderate-severe UC

This study assessed the comparative efficacy and safety of different therapies as first-line and second-line agents for moderate-severe ulcerative colitis. What is the optimal regimen? Alimentary Pharmacology & Therapeutics

EU approves first-line use of AZ’ Tagrisso in lung cancer

AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.

Upgrade, Inc. Introduces Personal Credit Line

With an Upgrade Personal Credit Line, consumers can get approved for up to $50,000and have the control to request an advance on the line Read more...

NICE recommends tivozanib as first-line treatment for kidney cancer

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication

FDA clears first-line use for J&J's Darzalex

Front-line approval a milestone for blockbuster-tipped myeloma drug

Payers Want Evidence That Patient Already Tried First-line Therapy

Increasingly, payers require patients to try and fail “first-line” treatments before payers approve more costly treatments. Include supporting articles from the literature supporting off-label use, and ask physicians to supply statements on why the first-line therapy is not appropriate.

First-line renin–angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus

RedHill BioPharma (RDHL) - Continued GI product growth, CD PhIII data in 3M

Edison Investment Research - Pharmaceutical & healthcare - RedHill Biopharma : With its Q118 results, RedHill reported GI product revenues growing by 22% q-o-q to $2.4m in Q118. It also provided updates on its Phase III programmes. The last patient has been assessed against the primary endpoint in the RHB-104 first Phase III trial in Crohn’s disease (CD), and top-line data are expected by Au...

ASCO 2018: Merck’s Keytruda on top in first-line NSCLC

The much-anticipated latest installment of the first-line non-small cell lung cancer (NSCLC) battle took place at this year’s American Society...Read More... The post ASCO 2018: Merck’s Keytruda on top in first-line NSCLC appeared first on Pharmaceutical Technology.

ImmuPharma chairman and chief executive upbeat on Lupuzor; industry interest remains strong

The pair said the debate around the company's flagship drug is far more 'nuanced' than the top-line data might suggest, which explains why potential licensing partners are keen to continue talking to management

LineRanger robot: Innovative live-line inspection solution

About half of the Hydro-Québec transmission system consists of lines made up of conductor bundles. This type of line is also widely used around the Read more...

AZ's Tagrisso gets EU nod as first-line NSCLC therapy

The European Commission has approved AstraZeneca's Tagrisso, or osimertinib, as a first-line treatment for adult patients wit -More- 

First-line indication for Tagrisso in USA

The US Food and Drug Administration has approved Tagrisso (osimertinib) for the first-line treatment…

RedHill BioPharma (BPCRRDHL) - Continued GI product growth, CD PhIII data in 3M

Edison Investment Research - Investment Companies - BioPharma Credit - Pharmaceutical & healthcare - RedHill Biopharma : With its Q118 results, RedHill reported GI product revenues growing by 22% q-o-q to $2.4m in Q118. It also provided updates on its Phase III programmes. The last patient has been assessed against the primary endpoint in the RHB-104 first Phase III trial in Crohn’s disease ...

[Articles] Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study

Non-attribution of a cause in a high proportion of patients suggests that a substantial proportion of pSBI episodes might not have been due to infection. The predominance of bacterial causes among babies who died, however, indicates that appropriate prevention measures and management could substantially affect neonatal mortality. Susceptibility of bacterial isolates to first-line antibiotics empha...

5 Big Mistakes You Can Make When Selecting Your Cell Line Provider

Imagine you have spent months working with a cell line provider. You are proud to have found this specific one – cheap, fast and seemingly efficient. You already envision the lucrative commercial production of your therapeutic protein. But then reality ... This awesome article 5 Big Mistakes You Can Make When Selecting Your Cell Line Provider appeared first on Labiotech.eu. Be kind and don't...

Automatic Lubrication System Market Worth 958.5 Million USD by 2023

According to the new market research report "Automatic Lubrication System Market by Lubrication Type (Grease, Oil), System Type (Single-Line, Dual-Line, Multi-Line, Series Progressive, Circulating Oil, Read more...

Risk for Dysplastic or Neoplastic Progression of Irregular Z Line

Prospectively collected data support current guideline recommendations to forego biopsy in patients with an irregular Z line.

Allscripts Care Management Merges with CarePort Health to Build Care Coordination Tools

CarePort Health, an Allscripts company and pioneer in post-acute outcomes management, today announced it has assumed management of the Allscripts Care Management solution and services portfolio. This transition is part of a strategy to accelerate innovation for the Care Management platform. Together, the Care Management and CarePort platforms offer providers, payers and ACOs unparalleled visibili...

IMMJ Systems Partners with UKCloud Health to Launch “MediViewer Cloud”

UKCloud and Healthcare Electronic Document Management Systems (EDMS) provider IMMJ Systems have jointly announced the launch of “MediViewer Cloud” for secure, scalable, reliable, mission-critical services with best-in-class EDMS technology in line with the NHS Cloud guidelines* recently published by NHS Digital and NHS England.MediViewer is a game-changing next generation Electronic Document M...

Ipsen receives European first-line approval for Cabometyx

Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced renal cell carcinoma (RCC). The approval builds on the second line approval it had previously received in 2016, although negotiations with numerous European countries over the price of medicine have delayed access for many nations until recently. NICE gave approval for the use of ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks